NCT00776321View on ClinicalTrials.gov

Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Primary Hypercholesterolemia
Interventions
DRUG

Eprotirome

DRUG

Placebo

Trial Locations (1)

Unknown

Jens Kristensen, Huddinge

Sponsors

Lead Sponsor

Karo Bio AB
All Listed Sponsors
lead

Karo Bio AB

INDUSTRY

NCT00776321 - Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia | Biotech Hunter | Biotech Hunter